Hyderabad, July 1 -- A joint research by City-based startup ReaGene Innovations Private Limited and INDRAS Private Limited has suggested that repurposing ananti-diabetic drug may be useful in COVID-19 treatment. Ertugliflozin, the diabetes drug in question, is an FDA approved drug for type-2 diabetes. It removes excessive glucose through urine.

The repurposed drug, Ertugliflozin, from the in-vitro and in-silico studies, respectively, mightprovide a therapeutic solutionto the COVID-19 infection, ReaGene Innovations Private Limited and INDRAS Private Limited said.

"Their findings indicate that this repurposed drug not only binds effectively to the receptor binding domain of the spike protein of COVID-19 further blocks binding to human ACE...